Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

8.37USD
16 Feb 2018
Change (% chg)

$0.24 (+2.95%)
Prev Close
$8.13
Open
$8.16
Day's High
$8.47
Day's Low
$8.16
Volume
52,990
Avg. Vol
39,264
52-wk High
$9.26
52-wk Low
$3.21

Latest Key Developments (Source: Significant Developments)

Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING.  Full Article

Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018.ZAFGEN- INCREASED CASH POSITION DURING Q4, EXPECTS TO END CALENDAR YEAR 2017 WITH OVER $100 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES.ZAFGEN INC - WELL-CAPITALIZED TO SUPPORT ITS CLINICAL-STAGE DEVELOPMENT PROGRAMS BEYOND FIRST HALF OF 2019.ZAFGEN - ‍ENTERED A $20 MILLION VENTURE DEBT FINANCING AGREEMENT WITH SILICON VALLEY BANK ON DEC 29, EXTENDING EXPECTED CASH RUNWAY BEYOND H1 2019​.ZAFGEN INC - TOPLINE DATA ARE EXPECTED IN MID-YEAR 2018 FOR ZGN-1258.ZAFGEN -FOR ZGN-1258,‍ BEGINNING IND APPLICATION-ENABLING WORK IN Q1 FOR FILING WITH U.S. FDA, BEGINNING PHASE 1 CLINICAL DEVELOPMENT BY END OF YEAR​.  Full Article

Zafgen reports Q3 loss per share $0.46
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Zafgen Inc :Zafgen reports third quarter 2017 financial results.Q3 loss per share $0.46.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Zafgen- continues to expect its cash, cash equivalents and marketable securities balance to be greater than $70 million as of december 31, 2017​.Zafgen Inc - ‍initiated phase 2 clinical trial for second generation metap2 inhibitor ZGN-1061​.  Full Article

Zafgen appoints Jeffrey Hatfield as CEO
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Zafgen Inc ::Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer.Zafgen Inc - Hatfield and Hughes will serve on Zafgen's board of directors​.  Full Article

Zafgen posts Q2 shr loss $0.55
Thursday, 4 Aug 2016 

Zafgen Inc : Q2 loss per share $0.55 . Zafgen reports second quarter 2016 financial results . Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S .Says expects that its cash, cash equivalents and marketable securities balance will be greater than $125 million at december 31, 2016.  Full Article

Zafgen Q1 loss per share $0.65
Tuesday, 10 May 2016 

Zafgen Inc : Reported a net loss for q1 of $0.65 per share . Expects that its cash, cash equivalents and marketable securities balance will be greater than $100 million at December 31, 2016 . Zafgen inc says expect to have more clarity on potential path forward for beloranib in PWS over next few months . Zafgen reports first quarter 2016 financial results . Q1 loss per share $0.65 .Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln

* ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING Source text: [http://bit.ly/2Earwn6] Further company coverage: